Class III โ€” Low Risk

Low risk โ€” use of or exposure to this product is not likely to cause adverse health consequences.

Diltiazem HCl Extended-release Capsules Recalled by Mylan Institutional, Inc. (d.b.a. UDL Laboratories) Due to Failed Impurities/Degradation Specifications: High out-of-specification results for a...

Date: July 3, 2014
Company: Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Status: Terminated
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Mylan Institutional, Inc. (d.b.a. UDL Laboratories) directly.

Affected Products

Diltiazem HCl Extended-release Capsules, USP, 120 mg, packaged in 80 Capsules (8 x 10) blister cards per carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 51079-947-08.

Quantity: 1,184 cartons

Why Was This Recalled?

Failed Impurities/Degradation Specifications: High out-of-specification results for a related compound obtained during routine stability testing.

Where Was This Sold?

This product was distributed nationwide across all 50 states.

Affected (51 states)Not affected

About Mylan Institutional, Inc. (d.b.a. UDL Laboratories)

Mylan Institutional, Inc. (d.b.a. UDL Laboratories) has 22 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report